Phenom Recognized as a Strategic Leader in Fosway’s 2022 9-Grid™ for Talent Acquisition for Second Consecutive Year
Phenom, the leading AI-powered talent experience platform, has been named a Strategic Leader in the 2022 Fosway 9-Grid™ for Talent Acquisition for the second year in a row. Fosway identifies Strategic Leaders as companies that provide a rich suite of capability across a broad scope of features and have the sophistication to consistently meet the needs of complex enterprise-scale customers. According to Fosway, Phenom has proven its ability to deliver higher levels of innovation, customer impact and advocacy compared to alternatives in the market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220503006092/en/
Phenom positioned as Strategic Leader in Fosway 9-Grid (Graphic: Business Wire)
With the highest job vacancy rate Europe has seen in 14 years, the talent shortage has developed into a crisis that extends far beyond human resources. To better connect with candidates and quickly fill open roles, CHROs and CEOs from today’s leading enterprises are choosing systems of intelligence to automate tasks and provide personalised experiences that job seekers expect in today’s competitive talent market.
Phenom’s position as a Strategic Leader reinforces that its Talent Experience Management (TXM) platform is enabling enterprises with the AI and automation necessary to quickly identify and hire best-fit talent, and an intelligent talent marketplace to develop and retain their best employees.
“Organisations are facing acute recruitment challenges that require innovative approaches to talent acquisition," said David Wilson, CEO, Fosway Group. "Phenom has consolidated its position as a Strategic Leader on the 2022 Fosway 9-Grid™ for Talent Acquisition through its focus on innovation and harnessing talent intelligence to deliver better recruitment outcomes for customers."
In 2021, 50,000 recruiters, talent marketers and hiring managers used Phenom to hire over 2 million people and engage over 5 million employees. Built on a vast network of data, contextual industry models and deep learning, the Phenom TXM platform is empowering organisations to:
- Engage & hire best-fit candidates faster: Connecting job seekers with relevant job recommendations and content based on skills, experience and location with a personalised Career Site, conversational Chatbot and CMS.
- Improve recruiter productivity: Identifying best-fit talent for open roles and automating tedious administrative tasks with a talent CRM, Campaigns, AI Scheduling, Video Assessments and AI Insights.
- Develop and retain employees: Fostering employee engagement, growth, and retention with an Internal Talent Marketplace, Career Pathing, Internal Mobility, Gigs, Diversity, Equity & Inclusion and Employee Resource Groups.
- Enable hiring managers: Streamlining collaboration with managers and elevating meaningful insights through talent analytics.
AXA, a global insurance company and Phenom customer, continues to see new value in the Phenom platform every day.
“With Phenom, it’s easier than ever for employees and candidates to explore open jobs across our organisation. Since the platform is constantly capturing and analyzing data, it’s delivering personalized experiences to help everyone find the right fit. When we’re able to connect people with opportunities where they can shape the way they work and realize their potential, that’s the greatest achievement of all,” said Amanda Vaughan, Global Head of Talent & Learning at AXA.
“As enterprises rely on talent experience to meet hiring demands in EMEA, maintaining our position as a Strategic Leader in Fosway’s Talent Acquisition grid signifies how we’re planting our roots in the HR technology market,” said Jeff Carey, senior vice president of international business at Phenom. “Our customers chose Phenom as the AI-powered solution to not only help them find candidates faster and retain talent today — they’re also investing in our constant innovation to ensure they’re future-proofed for the inevitable demands that will arise tomorrow.”
Companies across EMEA are successfully adopting Phenom’s talent experience platform to help candidates find the right job faster, recruiters discover best-fit talent, employees learn and evolve and managers build their teams. To support the growing need for Talent Experience Management, Phenom acquired three Europe-based companies and now has employees based in countries including Germany, France, Ireland, the Netherlands, Switzerland, Italy, Spain and the United Kingdom.
To learn more about Phenom’s Strategic Leader position, please visit their blog.
To see Fosway’s full analysis, check out their 2022 9-grid™.
About Phenom
Phenom is a global HR technology company with a purpose to help a billion people find the right job. With an expertise in building AI-powered, scalable solutions, Phenom Talent Experience Management (TXM) personalises and automates the talent journey for candidates, recruiters, employees and managers with its Career Site, Chatbot, CRM, CMS, SMS and Email Campaigns, University Recruiting, Internal Mobility, Career Pathing, Diversity & Inclusion, Talent Marketplace, Gigs, Referrals, Hiring Manager and Analytics. As a result, employers improve their talent acquisition and talent management efforts by helping candidates find the right job, employees grow and evolve, recruiters discover top talent, and managers build teams faster. Phenom was a winner in the Business Intelligence Group’s 2021 Artificial Intelligence Excellence Awards program for its sophisticated machine learning capabilities and was ranked among the fastest-growing private companies in the 2021 Inc. 5000.
Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.
For more information, please visit www.phenom.com. Connect with Phenom on LinkedIn, Twitter, Facebook, YouTube and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503006092/en/
Contact information
Media:
Jennifer Lyons
Director, Global Communications
267-379-5066
jennifer.lyons@phenompeople.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom